Mario Balsa, Medical Oncology resident at Catalan Institute of Oncology, shared a post on X about a recent article by B.A. Maiorano et al. published in ESMO OPEN:
“New in ESMO Open: real-world outcomes of ICI rechallenge in advanced UC (n=292; 86% bladder, 14% upper tract;)
mOS 20.5 mo, PFS 10.3 mo
≥12m interval → longer OS
Prior ICI in non-M1 setting → best outcomes
Anti-PD1 after anti-PD-L1 → longest benefit (18.2 mo)
Rechallenge isn’t common…but in selected patients, the immune spark can light twice.”
Title: Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study
Authors: B.A. Maiorano, A. Cigliola, V. Tateo, C. Mercinelli, G.L. Pastorino, N. Dizman, H. Ebrahimi, S.K. Pal, S. Gupta, P. Grivas, A.M. Kamat, P.E. Spiess, N. Agarwal, A. Necchi
Read the Full Article on ESMO OPEN
More posts featuring Mario Balsa.
